|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Special Report
Intuitive Surgical's Selloff Sets Up a 30% Rebound OpportunityReported by Thomas Hughes. Article Published: 4/23/2026. 
Key Points
- Instuitive Surgical hit bottom in early 2026 and is set up to rebound robustly.
- Accelerting device placement, procedure volume, and consumable supplies underpin the growth outlook.
- Competition exists but trails significantly, leaving this company with a wide moat.
- Special Report: Elon Musk already made me a “wealthy man”
Intuitive Surgical’s (NASDAQ: ISRG) primary headwinds are its elevated valuation and slowing growth. That combination has weighed on the stock since early 2025 and is unlikely to disappear soon. Still, today’s valuation already reflects a solid growth outlook, which may ultimately understate the company’s potential. That potential lies in the dominance of robotic surgical procedures. The company has a first-mover advantage, with an installed base of more than 12,000 devices and still growing. In that context, a 45x valuation relative to current-year earnings is only a modest hurdle, especially given the possibility of a 50% or greater increase in the stock price over the next few years.
And that assumes the long-term forecasts are accurate. As it stands, Intuitive Surgical consistently outperforms expectations, and device deployments and procedure volumes continue to rise. The more likely scenario is that ISRG continues to outperform and drives a bullish revision cycle over the long term. Market Overreaction Sets Up ISRG OpportunityAnalysts played a role in ISRG’s stock price decline in 2026. Leading up to the fiscal Q1 2026 release, price target revisions were trending lower, but the market overreacted, creating a deep-value opportunity. The revision trend still supports the consensus price target, which points to more than 30% upside from critical support levels, and there is strong conviction behind that forecast. MarketBeat tracks 25 analysts, who rate the stock a consensus Moderate Buy, with a 68% buy-side bias echoed in institutional activity. The institutional activity is telling. Institutions own more than 80% of the stock and have been accumulating throughout the correction. Their buying accelerated into Q1 2026 and remained strong in the first weeks of Q2. The trailing 12-month balance is nearly $2-to-$1 in favor of buyers, with Q1 and Q2 activity reflecting accelerating demand. The takeaway is that ISRG has a solid floor in the $445 to $450 range and is positioned for a robust rebound in Q2 and the latter part of 2026. Stock price action reflects the institutional activity, with declines stalling near $445 and rebounds following. The setup in mid-Q2 points to a recovery, with the market finding support at this critical level and advancing after the Q1 release. Indicators such as MACD and stochastic are also aligned, suggesting a trend-following move that could take the stock back to record levels. Technical hurdles include the long-term 150-day exponential moving average near $500 and resistance at prior peaks around $560 and $600. Buybacks Add Leverage: Underpin Stock Price OutlookBuybacks are another reason this stock could set new highs. Not only is the company outperforming and forward estimates improving, but buybacks have also increased shareholder leverage. The Q1 release showed more than $1.1 billion in quarterly repurchases, enough to reduce the share count by 0.15% sequentially and by approximately 1.3% from the prior-year period, while preserving the capacity to keep buying shares at a robust pace. Intuitive Surgical’s balance sheet reflects the effects of buybacks and acquisitions, but those are offset by strong cash flow and the leverage gained for shareholders. Key details include lower cash, offset by reduced liabilities and relatively steady equity. In this scenario, ISRG can continue repurchasing shares while maintaining balance-sheet health indefinitely, including a zero-debt profile. As it stands, Intuitive Surgical’s balance sheet is net cash relative to total liabilities, with cash more than 3.15x liabilities, potentially making it the strongest balance sheet on Wall Street. Intuitive Surgical’s Q1 Release Triggers Market ReboundIntuitive Surgical had a robust Q1, reinforcing its trends and suggesting that forward estimates may be far off the mark. Net revenue of $2.77 billion rose 23.1% year over year, exceeding consensus by more than 550 basis points (bps). Growth was driven by device placement, up 17%, procedure volume, up 17%, and instrument sales, up 23%. The installed base grew 12%, pointing to continued gains in upcoming quarters, and margins improved. The company’s adjusted net income grew by 36%, outpacing revenue growth by more than 1,300 bps, and is expected to remain strong in the quarters ahead. Guidance calls for full-year Da Vinci device growth of approximately 14.5%, with procedures and instrument sales expected to follow suit. The biggest risk for the company, aside from valuation, is competition, but rivals are still trailing significantly. The closest competitor is Medtronic’s (NYSE: MDT) Hugo device, which has found success in overseas markets but is still in its early rollout stages. Catalysts for ISRG include the early success of Da Vinci 5, the AI opportunity and expansion into international markets. Japan, specifically, recently approved seven new robotic procedures and is seen as a significant growth driver. |
No comments:
Post a Comment